Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety\nof travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed\ncombination ophthalmic solution in patients with open-angle glaucoma and\nocular hypertension. Methods: In this prospective, multicentre clinical trial,\n62 patients received travoprost 0.004% (n = 31) or travoprost 0.004% and beta-\nblocker 0.5% fixed combination (n = 31). Efficacy and safety were compared\nacross treatment groups over 2 years. IOP reduction and adverse events\nwere examined at 3, 6, 12 and 24 months for each group. Results: Mean IOP\nat the first visit in the travoprost 0.004% group was 26.4 (SD �± 2.1), and travoprost\n0.004%/timolol 0.5% group was 26.3 (SD �± 2.1). Mean IOP after 24\nmonths in the travoprost 0.004% group was 20.5 (SD �± 1.5) and travoprost\n0.004%/timolol 0.5% group was 18.5 (SD �± 1.5). There were statistically significant\ndifferences in IOP in both eyes after third visit (after 1 year) and\nfourth visit (after 2 years). Conclusion: After 2 year of treatment, travoprost\n0.004%/timolol 0.5% produced clinically relevant IOP reductions in patients\nwith open-angle glaucoma or ocular hypertension that were greater than those\nproduced by travoprost 0.004% alone.
Loading....